RGENIX Announces Company Name Change to Inspirna and Expands Board of Directors
30 Sep 2021 //
BUSINESSWIRE
RGENIX Presents Results from Preclinical Safety and Efficacy Studies of RGX-019
22 Jun 2020 //
BUSINESSWIRE
RGENIX Presents Biomarker and Efficacy Results from Phase 1of RGX-104
22 Jun 2020 //
BUSINESSWIRE
RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS
29 May 2020 //
BUSINESSWIRE